Chronic idiopathic constipation is defined by the infrequent or difficult passage of the stool for a period of at least three months. It is the cause of 2.5 million visits to physicians and 92,000 hospitalizations annually. “AMITIZA has been shown to deliver targeted and predictable relief to people with chronic idiopathic constipation, and we believe that through its novel mechanism of action, this drug may help fill an important therapeutic gap for many patients.”Ĭonstipation is one of the most common digestive complaints, affecting more than 30 million adults in the United States. “Takeda looks forward to working with Sucampo to successfully launch AMITIZA and help make it a trusted and valuable therapy for the treatment of chronic idiopathic constipation,” said Art Rice, general manager, Gastroenterology. The AMITIZA sales force in the United States will comprise representatives from both companies. “Unlike many treatments that may fail to control symptoms adequately or lose effectiveness with time, AMITIZA provides fast and predictable relief of chronic idiopathic constipation.”ĪMITIZA is developed by Sucampo Pharmaceuticals, Inc., and will be jointly marketed in the United States by Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceuticals North America, Inc. “The availability of AMITIZATM is exciting news for the millions of Americans who suffer from chronic idiopathic constipation and deal with its daily consequences,” said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine. Additionally, these symptomatic improvements lasted over the six to12 month treatment period.
In clinical trials, 60 percent of patients who used AMITIZA experienced a spontaneous bowel movement within the first 24 hours.ĪMITIZA improved signs and symptoms related to chronic constipation, including abdominal bloating, discomfort, stool consistency and straining. “As a science-driven pharmaceutical company, Sucampo is pleased to work with Takeda Pharmaceuticals North America to make this innovative new therapeutic option available to physicians and patients in the United States.”ĪMITIZA works by increasing fluid secretion locally in the small intestine by activating the ClC-2 chloride channel, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation. “AMITIZA is an important new option for people living with chronic idiopathic constipation who may be unsatisfied with traditional treatment options, including lifestyle and dietary changes, laxatives and stool softeners,” said Sachiko Kuno, Ph.D., co-founder, president and chief executive officer of Sucampo.
#Amitiza 24 mcg Activator#
AMITIZA (pronounced ahm-e-TEASE-a) is the first selective chloride channel activator approved for therapeutic use in chronic idiopathic constipation, a condition that affects both men and women and affects patients over the age of 65 more frequently.
Food and Drug Administration (FDA) in January 2006, is now available by prescription in pharmacies across the United States for the treatment of chronic idiopathic constipation in adults. and Takeda Pharmaceuticals North America, Inc., announced today that AMITIZA™ (lubiprostone), 24-mcg soft-gel capsules, approved by the U.S.
Bethesda, Md., and Lincolnshire, Il., Ap– Sucampo Pharmaceuticals, Inc.